PLEURA DISEASEPhase 2/3ESPBNCT07572019
Ultrasound Guided Erectror Spinae Block Versus Intracavitary During Medical Thoracoscopy
A Phase 2/3 study testing ultrasound-guided erector spinae plane block in medical pleuroscopy and Intracavitary anaesthesia ICA in people with PLEURA DISEASE, run by Kafrelsheikh University.
Trial summary
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri-procedural (intraoperative and post-operative 12 hours) nalbuphine consumption (mg) during medical thoracoscopy. Read more about this study
- Who is it for?
- Ages 25 to 65 years
- Conditions the study is for
- PLEURA DISEASE
- What is being tested?
- ultrasound-guided erector spinae plane block in medical pleuroscopy and Intracavitary anaesthesia ICA
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 May 2026to 20 Jul 2026
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 100 patients belonging to American Society of Anesthesiologists (ASA) I-III scheduled for medical thoracoscopy under adequate sedation and analgesia.
Who cannot join
- Patients will be excluded if; history of allergy or contraindication to any of the studied drugs, BMI more than 35 kg/m2 chronic opioid use or abuse, patients for whom ESPB block is contraindicated (patient refusal, coagulation disorder, skin infection at the injection site), history of post-thoracotomy, chest wall deformity, severe uncontrolled comorbidity, intubated patients, or if the interventional physician wants general anaesthesia from the start
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Ultrasound-Guided Erector Spinae Plane Block Versus Intracavitary Local Anaesthesia for Peri-procedural Analgesia During Medical Thoracoscopy: A Randomized Control Trial
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri-procedural (intraoperative and post-operative 12 hours) nalbuphine consumption (mg) during medical thoracoscopy. Secondary aims: Time to first rescue analgesia, postoperative VAS, haemodynamics, recovery time (Aldert > 9), and adverse events
- Conditions
- PLEURA DISEASE
- Being tested
- ultrasound-guided erector spinae plane block in medical pleuroscopy, Intracavitary anaesthesia ICA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ultrasound-guided erector spinae plane block in medical pleuroscopyProcedure or surgery
On the lateral decubitus position, under full aseptic technique; a high frequency (5-13 MHz) linear probe (or curvilinear in obese patients) of ultrasound covered sterilely will be placed in a parasagittal longitudinal orientation approximately 3 cm lateral to the spinous process to identify the trapezius, rhomboid major (if present), erector spinae muscle and thehyperechoic transverse process with its acoustic shadow, with the target being the fascial plane deep to the erector spinae muscle and superficial to the transverse process; the needle will be inserted in-plane in a cranial-to-caudal direction under real-time ultrasound guidance until it contacts the transverse process, after which 1-3 ml of normal saline is injected to confirm correct plane by lifting the erector spinae muscle off the transverse process, then following negative aspiration 20 ml of 0.25% bupivacaine at each level (10 ml 0.5% bupivacaine + 10 ml normal saline ) will be injected incrementally
Intracavitary anaesthesia ICAProcedure or surgery
After skin infiltration with lidocaine 2%, at the entry point of the trocar, small (2-4 cm) skin incision in the chest wall will be done, A trocar will be introduced into the pleural cavity. If necessary, air is introduced to allow the lung to collapse, creating space to view the pleural surface. The thoracoscope will be inserted to visualize the pleura. The interventional pulmonologist will receive the pre-prepared syringe from the block anaesthetist and will administer the solution intracavitarily via the thoracoscope working channel, without knowledge of its contents. In both groups, a total volume of 40 mL of solution is administered: 20 mL is sprayed over the costal, diaphragmatic, and mediastinal pleura via the thoracoscope working channel, and an additional 20 mL is injected through the chest tube inserted at the end of the procedure , 10-mL normal saline flush, and the chest tube is then clamped for 5 minutes
| Study group | Role | What they receive |
|---|---|---|
| 50 patients will receive two levels of ultrasound-guided erector spinae plane block (ESPB) at T5 an | Active comparator | Not described Receives: Procedure: ultrasound-guided erector spinae plane block in medical pleuroscopy |
| patients will receive intracavitary anaesthesia ICA with total volume 40 ml, 20 ml of 0.25% bu | Active comparator | Not described Receives: Procedure: Intracavitary anaesthesia ICA |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri procedural nalbuphine (mg) consumption during medical thoracoscopy
Measured: intraoperative and post-operative 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2026
- Study start15 May 2026 (estimated)
- Primary completion15 Jul 2026 (estimated)
- Study completion20 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PLEURA DISEASEStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Donia Hany Saad, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07572019
- Sponsor's protocol ID
- Medical pleuroscopy
- Acronym
- ESPB
- Status last verified
- Apr 2026
- First submitted
- 30 Apr 2026
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-Guided Erector Spinae Plane Block Versus Intracavitary Local Anaesthesia for Peri-procedural Analgesia During Medical Thoracoscopy: A Randomized Control Trial
- ClinicalTrials.gov ID
- NCT07572019
- Acronym / sponsor ID
- ESPB / Medical pleuroscopy
- Conditions
- PLEURA DISEASE
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 15 May 2026 (estimated)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 20 Jul 2026 (estimated)
- First posted
- 7 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri-procedural (intraoperative and post-operative 12 hours) nalbuphine consumption (mg) during medical thoracoscopy. Secondary aims: Time to first rescue analgesia, postoperative VAS, haemodynamics, recovery time (Aldert > 9), and adverse events
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 50 patients will receive two levels of ultrasound-guided erector spinae plane block (ESPB) at T5 an | Active comparator | Procedure: ultrasound-guided erector spinae plane block in medical pleuroscopy |
| patients will receive intracavitary anaesthesia ICA with total volume 40 ml, 20 ml of 0.25% bu | Active comparator | Procedure: Intracavitary anaesthesia ICA |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 100 patients belonging to American Society of Anesthesiologists (ASA) I-III scheduled for medical thoracoscopy under adequate sedation and analgesia.
Key exclusion criteria (1 listed)
- Patients will be excluded if; history of allergy or contraindication to any of the studied drugs, BMI more than 35 kg/m2 chronic opioid use or abuse, patients for whom ESPB block is contraindicated (patient refusal, coagulation disorder, skin infection at the injection site), history of post-thoracotomy, chest wall deformity, severe uncontrolled comorbidity, intubated patients, or if the interventional physician wants general anaesthesia from the start
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ultrasound-guided erector spinae plane block in medical pleuroscopyOn the lateral decubitus position, under full aseptic technique; a high frequency (5-13 MHz) linear probe (or curvilinear in obese patients) of ultrasound covered sterilely will be placed in a parasagittal longitudinal orientation approximately 3 cm lateral to the spinous process to identify the trapezius, rhomboid major (if present), erector spinae muscle and thehyperechoic transverse process with its acoustic shadow, with the target being the fascial plane deep to the erector spinae muscle and superficial to the transverse process; the needle will be inserted in-plane in a cranial-to-caudal direction under real-time ultrasound guidance until it contacts the transverse process, after which 1-3 ml of normal saline is injected to confirm correct plane by lifting the erector spinae muscle off the transverse process, then following negative aspiration 20 ml of 0.25% bupivacaine at each level (10 ml 0.5% bupivacaine + 10 ml normal saline ) will be injected incrementally | Procedure or surgery | 50 patients will receive two levels of ultrasound-guided erector spinae plane block (ESPB) at T5 an |
| Intracavitary anaesthesia ICAAfter skin infiltration with lidocaine 2%, at the entry point of the trocar, small (2-4 cm) skin incision in the chest wall will be done, A trocar will be introduced into the pleural cavity. If necessary, air is introduced to allow the lung to collapse, creating space to view the pleural surface. The thoracoscope will be inserted to visualize the pleura. The interventional pulmonologist will receive the pre-prepared syringe from the block anaesthetist and will administer the solution intracavitarily via the thoracoscope working channel, without knowledge of its contents. In both groups, a total volume of 40 mL of solution is administered: 20 mL is sprayed over the costal, diaphragmatic, and mediastinal pleura via the thoracoscope working channel, and an additional 20 mL is injected through the chest tube inserted at the end of the procedure , 10-mL normal saline flush, and the chest tube is then clamped for 5 minutes | Procedure or surgery | patients will receive intracavitary anaesthesia ICA with total volume 40 ml, 20 ml of 0.25% bu |
Primary outcome
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri procedural nalbuphine (mg) consumption during medical thoracoscopy
Time frame: intraoperative and post-operative 12 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- Individual participant dataSharing planned: No
Related trials for PLEURA DISEASE
RecruitingObservational study
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS
Recruiting
Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block
Lung Cancer
RecruitingPhase 1
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Malignant Pleural Effusion, Malignant Mesothelioma
RecruitingPhase 2
A Study of Sacituzumab Govitecan in People With Mesothelioma
Mesothelioma, Mesotheliomas Pleural
RecruitingPhase 1
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Malignant Pleural Effusion, Malignant Mesothelioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing ultrasound-guided erector spinae plane block in medical pleuroscopy and Intracavitary anaesthesia ICA in people with PLEURA DISEASE, run by Kafrelsheikh University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Donia Hany Hany, MD (01014498540, doniahany1788@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri procedural nalbuphine (mg) consumption during medical thoracoscopy (time frame: intraoperative and post-operative 12 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.